<?xml version='1.0' encoding='utf-8'?>
<regulation prefix="Regulation" num=".06" citation="COMAR 31.05.01.06" title_num="31" subtitle_num="05" chapter_num="01" heading="Description of Actuarial Memorandum Including an Asset Adequacy Analysis and Regulatory Asset Adequacy Issues Summary.">
  <paragraph num="A.">
    <text>General.</text>
    <paragraph num="(1)">
      <text>In accordance with Insurance Article, §5-201, Annotated Code of Maryland, the appointed actuary shall prepare a memorandum to the company describing the analysis done in support of the actuary's opinion regarding the reserves. The memorandum shall be made available for examination by the Commissioner upon the Commissioner's request.</text>
    </paragraph>
    <paragraph num="(2)">
      <text>In preparing the memorandum, the appointed actuary may rely on, and include as a part of the actuary's own memorandum, memoranda prepared and signed by other actuaries who are qualified within the meaning of Regulation .02B(7) of this chapter, with respect to the areas covered in those memoranda, and so state in their memoranda.</text>
    </paragraph>
    <paragraph num="(3)">
      <text>Memoranda.</text>
      <paragraph num="(a)">
        <text>If the Commissioner requests a memorandum, the Commissioner may designate a qualified actuary to review the opinion and prepare a supporting memorandum, if:</text>
        <paragraph num="(i)">
          <text>No memorandum exists; or</text>
        </paragraph>
        <paragraph num="(ii)">
          <text>The Commissioner finds that the analysis described in the memorandum fails to meet the standards of the Actuarial Standards Board or the standards and requirements of this chapter.</text>
        </paragraph>
      </paragraph>
      <paragraph num="(b)">
        <text>The reasonable and necessary expense of the independent review shall be paid by the company, but the review shall be directed and controlled by the Commissioner.</text>
      </paragraph>
    </paragraph>
    <paragraph num="(4)">
      <text>Company Data.</text>
      <paragraph num="(a)">
        <text>The reviewing actuary has the same status as an examiner for purposes of obtaining data from the company. The work papers and documentation of the reviewing actuary shall be retained by the Commissioner.</text>
      </paragraph>
      <paragraph num="(b)">
        <text>Information provided by the company to the reviewing actuary and included in the work papers:</text>
        <paragraph num="(i)">
          <text>Is considered as material provided by the company to the Commissioner; and</text>
        </paragraph>
        <paragraph num="(ii)">
          <text>Shall be kept confidential to the same extent as is prescribed by law with respect to other material provided by the company to the Commissioner pursuant to Insurance Article, §2-209, Annotated Code of Maryland.</text>
        </paragraph>
      </paragraph>
      <paragraph num="(c)">
        <text>The reviewing actuary may not be an employee of a consulting firm involved with the preparation of any prior memorandum or opinion for the company pursuant to this regulation for the current year or any one of the preceding 3 years.</text>
      </paragraph>
    </paragraph>
    <paragraph num="(5)">
      <text>Asset Adequacy Issues Summary.</text>
      <paragraph num="(a)">
        <text>In accordance with Insurance Article, §5-201, Annotated Code of Maryland, the appointed actuary shall prepare a regulatory asset adequacy issues summary, the contents of which are specified in §D of this regulation.</text>
      </paragraph>
      <paragraph num="(b)">
        <text>The regulatory asset adequacy issues summary shall be submitted not later than March 15 of the year following the year for which a statement of actuarial opinion based on asset adequacy is required.</text>
      </paragraph>
      <paragraph num="(c)">
        <text>The regulatory asset adequacy issues summary shall be kept confidential to the same extent and under the same conditions as the actuarial memorandum.</text>
      </paragraph>
    </paragraph>
  </paragraph>
  <paragraph num="B.">
    <text>Details of Memorandum Section Documenting Asset Adequacy Analysis. When an actuarial opinion under Regulation .05 of this chapter is provided, the memorandum shall demonstrate that the analysis has been done in accordance with the standards for asset adequacy analysis referred to in Regulation .03C of this chapter and any additional standards under this chapter. It shall specify:</text>
    <paragraph num="(1)">
      <text>For reserves:</text>
      <paragraph num="(a)">
        <text>Product descriptions including market description, underwriting, and other aspects of a risk profile, and the specific risks the appointed actuary considers significant;</text>
      </paragraph>
      <paragraph num="(b)">
        <text>Source of liability in force;</text>
      </paragraph>
      <paragraph num="(c)">
        <text>Reserve method and basis;</text>
      </paragraph>
      <paragraph num="(d)">
        <text>Investment reserves;</text>
      </paragraph>
      <paragraph num="(e)">
        <text>Reinsurance arrangements;</text>
      </paragraph>
      <paragraph num="(f)">
        <text>Identification of any explicit or implied guarantees made by the general account in support of benefits provided through a separate account or under a separate account policy or contract, and the methods used by the appointed actuary to provide for the guarantees in the asset adequacy analysis; and</text>
      </paragraph>
      <paragraph num="(g)">
        <text>Documentation of assumptions to test reserves for the following:</text>
        <paragraph num="(i)">
          <text>Lapse rates (both base and excess);</text>
        </paragraph>
        <paragraph num="(ii)">
          <text>Interest crediting rate strategy;</text>
        </paragraph>
        <paragraph num="(iii)">
          <text>Mortality;</text>
        </paragraph>
        <paragraph num="(iv)">
          <text>Policyholder dividend strategy;</text>
        </paragraph>
        <paragraph num="(v)">
          <text>Competitor or market interest rate;</text>
        </paragraph>
        <paragraph num="(vi)">
          <text>Annuitization rates;</text>
        </paragraph>
        <paragraph num="(vii)">
          <text>Commissions and expenses; and</text>
        </paragraph>
        <paragraph num="(viii)">
          <text>Morbidity;</text>
        </paragraph>
      </paragraph>
    </paragraph>
    <paragraph num="(2)">
      <text>For assets:</text>
      <paragraph num="(a)">
        <text>Portfolio descriptions, including a risk profile disclosing the quality, distribution, and types of assets;</text>
      </paragraph>
      <paragraph num="(b)">
        <text>Investment and disinvestment assumptions;</text>
      </paragraph>
      <paragraph num="(c)">
        <text>Source of asset data;</text>
      </paragraph>
      <paragraph num="(d)">
        <text>Asset valuation bases; and</text>
      </paragraph>
      <paragraph num="(e)">
        <text>Documentation of assumptions made for:</text>
        <paragraph num="(i)">
          <text>Default costs;</text>
        </paragraph>
        <paragraph num="(ii)">
          <text>Bond call function;</text>
        </paragraph>
        <paragraph num="(iii)">
          <text>Mortgage prepayment function;</text>
        </paragraph>
        <paragraph num="(iv)">
          <text>Determining market value for assets sold due to disinvestment strategy; and</text>
        </paragraph>
        <paragraph num="(v)">
          <text>Determining yield on assets acquired through the investment strategy;</text>
        </paragraph>
      </paragraph>
    </paragraph>
    <paragraph num="(3)">
      <text>For the analysis basis:</text>
      <paragraph num="(a)">
        <text>Methodology;</text>
      </paragraph>
      <paragraph num="(b)">
        <text>Rationale for inclusion/exclusion of different blocks of business and how pertinent risks were analyzed;</text>
      </paragraph>
      <paragraph num="(c)">
        <text>Rationale for degree of rigor in analyzing different blocks of business, including the level of materiality that was used in determining how rigorously to analyze different blocks of business;</text>
      </paragraph>
      <paragraph num="(d)">
        <text>Criteria for determining asset adequacy, including the precise basis for determining if assets are adequate to cover reserves under moderately adverse conditions or other conditions as specified in relevant actuarial standards of practice; and</text>
      </paragraph>
      <paragraph num="(e)">
        <text>Whether the impact of federal income taxes was considered and the treatment of reinsurance in the asset adequacy analysis;</text>
      </paragraph>
    </paragraph>
    <paragraph num="(4)">
      <text>Summary of material changes in methods, procedures, or assumptions from the prior year's asset adequacy analysis;</text>
    </paragraph>
    <paragraph num="(5)">
      <text>Summary of results; and</text>
    </paragraph>
    <paragraph num="(6)">
      <text>Conclusion or conclusions.</text>
    </paragraph>
  </paragraph>
  <paragraph num="C.">
    <text>In §B(1) and (2) of this regulation, the documentation of the assumptions shall be such that an actuary reviewing the actuarial memorandum could form a conclusion as to the reasonableness of the assumptions.</text>
  </paragraph>
  <paragraph num="D.">
    <text>Details of the Regulatory Asset Adequacy Issues Summary.</text>
    <paragraph num="(1)">
      <text>The regulatory asset adequacy issues summary shall include:</text>
      <paragraph num="(a)">
        <text>Descriptions of the scenarios tested, including whether those scenarios are stochastic or deterministic, and the sensitivity testing done relative to those scenarios as follows:</text>
        <paragraph num="(i)">
          <text>If negative ending surplus results under certain tests in the aggregate, the actuary should describe those tests and the amount of additional reserve as of the valuation date which, if held, would eliminate the negative aggregate surplus values; and</text>
        </paragraph>
        <paragraph num="(ii)">
          <text>Ending surplus values shall be determined by either extending the projection period until the in-force and associated assets and liabilities at the end of the projection period are immaterial or by adjusting the surplus amount at the end of the projection period by an amount that appropriately estimates the value that can reasonably be expected to arise from the assets and liabilities remaining in force;</text>
        </paragraph>
      </paragraph>
      <paragraph num="(b)">
        <text>The extent to which the appointed actuary uses assumptions in the asset adequacy analysis that are materially different than the assumptions used in the previous asset adequacy analysis;</text>
      </paragraph>
      <paragraph num="(c)">
        <text>The amount of reserves and the identity of the product lines that had been subjected to asset adequacy analysis in the prior opinion but were not subject to analysis for the current opinion;</text>
      </paragraph>
      <paragraph num="(d)">
        <text>Comments on any interim results that may be of significant concern to the appointed actuary, for example, the impact of the insufficiency of assets to support the payment of benefits and expenses and the establishment of statutory reserves during one or more interim periods;</text>
      </paragraph>
      <paragraph num="(e)">
        <text>The methods used by the actuary to recognize the impact of reinsurance on the company's cash flows, including both assets and liabilities, under each of the scenarios tested; and</text>
      </paragraph>
      <paragraph num="(f)">
        <text>Whether the actuary has been satisfied that all options whether explicit or embedded, in any asset or liability, including but not limited to those affecting cash flows embedded in fixed income securities, and equity-like features in any investments, have been appropriately considered in the asset adequacy analysis.</text>
      </paragraph>
    </paragraph>
    <paragraph num="(2)">
      <text>The regulatory asset adequacy issues summary shall contain the name of the company for which the regulatory asset adequacy issues summary is being supplied and shall be signed and dated by the appointed actuary rendering the actuarial opinion.</text>
    </paragraph>
  </paragraph>
  <paragraph num="E.">
    <text>Conformity to Standards of Practice. The memorandum shall include a statement:</text>
  </paragraph>
  <paragraph num="F.">
    <text>Use of Assets Supporting the Interest Maintenance Reserve and the Asset Valuation Reserve.</text>
    <paragraph num="(1)">
      <text>An appropriate allocation of assets in the amount of the interest maintenance reserve (IMR), whether positive or negative, shall be used in any asset adequacy analysis.</text>
    </paragraph>
    <paragraph num="(2)">
      <text>Analysis of risks regarding asset default may include an appropriate allocation of assets supporting the asset valuation reserve (AVR), and these AVR assets may not be applied for any other risks with respect to reserve adequacy.</text>
    </paragraph>
    <paragraph num="(3)">
      <text>Analysis of these AVR assets and other risks may include assets supporting other mandatory or voluntary reserves available to the extent not used for risk analysis and reserve support.</text>
    </paragraph>
    <paragraph num="(4)">
      <text>The amount of the assets used for the AVR shall be disclosed in the Table of Reserves and Liabilities of the opinion and in the memorandum. The method used for selecting particular assets or allocated portions of assets shall be disclosed in the memorandum.</text>
    </paragraph>
  </paragraph>
  <paragraph num="G.">
    <text>Documentation. The appointed actuary shall retain on file, for at least 7 years, sufficient documentation so that it will be possible to determine:</text>
    <paragraph num="(1)">
      <text>The procedures followed;</text>
    </paragraph>
    <paragraph num="(2)">
      <text>The analyses performed;</text>
    </paragraph>
    <paragraph num="(3)">
      <text>The basis for assumptions; and</text>
    </paragraph>
    <paragraph num="(4)">
      <text>The results obtained.</text>
    </paragraph>
  </paragraph>
</regulation>